- Company
- Celltrion's Regkirona was approved for EUA in Indonesia
- by Kim, Jin-Gu Jul 22, 2021 05:52am
- Celltrion said on the 20th that the coronavirus 19 antibody treatment drug Regkirona (Regdanvimab) has obtained an emergency approval (EUA) from the BPOM. The Indonesian government has approved the emergency use of Regkirona for minor and secondary patients in the high-risk adult group with COVID-19. According to the COVID-19 real-time
- Company
- Why Keytruda’s smile wavers after passing CDRC deliberation
- by Eo, Yun-Ho Jul 21, 2021 05:52am
- The drug finally was able to pass deliberations by the Review Committee for Cancer Diseases, but still, the company's smile wavers due to the bitter aftertaste left by the committee’s ‘conditional’ approval. With MSD Korea’s cancer immunotherapy ‘Keytruda (pembrolizumab)’ passing deliberations by the Review Committee for Cancer Dise
- Company
- Antibiotic sales are decreasing due to prolonged COVID-19
- by Chon, Seung-Hyun Jul 21, 2021 05:51am
- The outpatient prescription market has also changed significantly as COVID-19 epidemic has been prolonged. The pharmaceutical market, which is mainly used for infectious diseases such as antibiotics, anti-septic drugs, and influenza (flu) treatments, has shrunk significantly. The flu treatment market has shrunk 99.9% in two years. According t
- Company
- Harvoni’s growth spurt despite Hep C market downturn
- by Nho, Byung Chul Jul 21, 2021 05:51am
- With the domestic hepatitis C treatment market externally contracting from &8361;120 billion to &8361;68 billion in three years, the rapid strides of growth made by Harvoni in the market is drawing attention. On the 20th, Dailypharm analyzed the hepatitis C treatment market based on IQVIA data. The overall sales in the Hep C market amou
- Policy
- GSK & SK Bio also stopped supplying TD vaccines
- by Lee, Tak-Sun Jul 21, 2021 05:51am
- SK Bioscience will also withdraw its products from the TD vaccine market that prevents diphtheria and tetanus in adults. GSK, which had been importing and supplying TD vaccines last year, also stopped supplying them in the Korean market. As a result, GC Pharma, which is manufacturing domestic drugs, is expected to strengthen its position in t
- Company
- Domestic Rx sales are showing strength in H1
- by An, Kyung-Jin Jul 21, 2021 05:51am
- Pfizer's treatment for dyslipidemia ranked first in outpatients in the first half of the year. Drugs developed with domestic technologies such as "Rosuzet" and "Zemimet" led by HK-Inoen's "K-CAB" have increased their market influence despite the chaos of COVID-19 outbreak. The originals of multinational pharmaceutical companies, which once h
- Company
- Patent ruling changes NOAC market…Eliquis surpasses Xarelto
- by Kim, Jin-Gu Jul 20, 2021 05:47am
- The Supreme Court’s ruling shook up the new oral anticoagulant (NOAC) market in the second quarter of this year. With Daiichi Sankyo’s ' Lixiana (Edoxaban) still in the lead, 'Eliquis(apixaban),’ which had experienced a decline in sales after its generics were released, made a successful rebound. On the other hand, Eliquis’s generics that
- Policy
- CSO expenditure report Act, effective immediately
- by Lee, Jeong-Hwan Jul 20, 2021 05:47am
- The government promulgated the revised Pharmacist Act today (20th), which includes restrictions on co-living and clinical 1+3 of generic and new drugs and mandatory preparation of CSO expenditure reports. In accordance with the revised Pharmaceutical Law, restrictions on 1+3 generic and improvement new drugs and regulations requiring CSOs
- Policy
- Kymriah reimbursement was not discussed at CDRC meeting
- by Lee, Jeong-Hwan Jul 20, 2021 05:47am
- The Korea Leukemia Patients Organization (KLPO) expressed its regrets to the government and Novartis Korea for excluding the first CAR-T treatment Kymriah from the agenda for deliberation at the Review Committee for Cancer Diseases meeting that was held on the 14th. On the 19th, KLPO said, “A disconcerting situation occurred. Kymriah wa
- Policy
- Pfizer vaccine available in Korea for ages 12 or older
- by Lee, Tak-Sun Jul 20, 2021 05:46am
- Pfizer's COVID-19 vaccine has become available in Korea for people over 12 years of age. The MFDS announced on the 16th that it has approved the change of Comirnaty, which can be used to prevent COVID-19 among people aged 12 and older. The dosage and indications of the vaccine can be diluted once with 0.3ml and inoculated additionally a
